Last reviewed · How we verify
NCT06205277: START
Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
trial testing Second TURBt in Bladder Cancer in 1,300 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | University of Trieste |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,300 |
| Start date | 1 January 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Second TURBt
Conditions studied
- Bladder Cancer — all drugs for Bladder Cancer →
- Non Muscle Invasive Bladder Cancer — all drugs for Non Muscle Invasive Bladder Cancer →
Sponsor
University of Trieste
Who can join
18 and older, any sex, with Bladder Cancer or Non Muscle Invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The START study is a multicentre retrospective project. The aim is to identify clinico-pathological predictors of residual tumor at time of second transurethral resection of bladder tumor (re-TURBt) and to identify well-selected candidates for a risk-adapted strategy in which this procedure could be safely spared.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06205277
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder Cancer
Currently open trials in the same condition.
- NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
Other University of Trieste trials
Trials by the same sponsor.
- NCT07430046 — Repurposing Mirtazapine in Rett Syndrome · Phase 2 · recruiting
- NCT07006571 — At-home Treatment With Cortico-spinal tDCS for Amyotrophic Lateral Sclerosis · NA · recruiting
- NCT06331416 — Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation · NA · recruiting
- NCT05984095 — Multiple Sclerosis Pelvic Floor Telerehabilitation · NA · completed
- NCT06433856 — Neuromuscular Responses to Recovery Techniques · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06205277 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Trieste
- Last refreshed: 12 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06205277.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing